Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study

摘要: There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for management major bleeding (MBEs) on rivaroxaban or apixaban. We investigated PCCs given MBEs Between 1 January 2014 October 2016, we prospectively included apixaban MBEs. The was assessed by using International Society Thrombosis Hemostasis Scientific Standardization Subcommittee criteria assessment management. safety outcomes were all-cause mortality within 30 days after treatment PCCs. A total 84 received reversal due to a MBE. at median (interquartile range) dose 2000 IU (1500-2000 IU). Intracranial hemorrhage (ICH) most common site requiring (n = 59; 70.2%), followed gastrointestinal 13 (15.5%) patients. Management as effective 58 (69.1%) ineffective 26 (30.9%) Most hemostasis had ICH 16; 61.5%). Two developed an ischemic stroke, occurring 5 10 PCC. Twenty-seven (32%) died administration associated cases low risk thromboembolism. Our findings are limited absence control group study.